Signia
Financiado
An innovative drug development and repurposing platform for rapid identification...
An innovative drug development and repurposing platform for rapid identification and validation of antimicrobial therapeutics
Pharma industry is facing the challenge of high-cost and time-consuming processes for de novo drug development (€1-2 billion and 10-17 years per marketed drug), also influenced by high failure rates (only 10% of drug candidates ar...
Pharma industry is facing the challenge of high-cost and time-consuming processes for de novo drug development (€1-2 billion and 10-17 years per marketed drug), also influenced by high failure rates (only 10% of drug candidates are approved for market entry). As a result, an increasing number of firms seek alliances based on repurposing existing drugs for new indications to deliver the needed productivity increases, shifting the focus of R&D to smaller biotech companies.
Among all infectious diseases, acute respiratory tract infections are the main source of acute diseases worldwide with over 17.5B deaths per year, notably killing newborns and young children. They are caused by over 200 viruses and handful virus-bacteria coinfections; however, today we only have vaccines and few treatments for Influenza and respiratory syncytial virus.
Signia is a French start-up offering a disruptive solution to combat these emerging infections globally; a drug development platform for next-generation antimicrobial treatments, by repurposing ready-marketed drugs and repositioning unsuccessful pharma pipelines candidates. Signia strategy involves a complete paradigm shift, based on targeting the global response of the host cell instead of a specific molecular determinant of the pathogen.
Our innovation will not only give rise to better treatments against respiratory infections and significant shortening of response time to widespread outbreaks, but also will enable both a rapid transition of drugs from the pipeline to the market and a rapid return of investment for pharmas.
Phase 2 will let us reach the full capability of our platform and the clinical validation of the optimized nebulized Diltiazem, our drug candidates at the most advanced stage of validation as repurposed host-targeted inhibitor of influenza infection. We forecast €31M revenues (with a ROI of 9.72 with a corresponding EBITDA of 70.51% after 5 years in the market) and increase our company´s workforce to 14.
ver más
Duración del proyecto: 36 meses
Fecha Inicio: 2020-05-14
Fecha Fin: 2023-05-31
Fecha Fin: 2023-05-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-05-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
SIGNIA THERAPEUTICS
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
490.00K€ |
Participante